WHO Drug Information Vol. 14, No. 2, 2000
(2000; 73 pages) Voir le document au format PDF
Table des matières
Afficher le documentPreface
Ouvrir ce répertoire et afficher son contenuGeneral Policy Issues
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Fermer ce répertoireRegulatory and Safety Matters
Afficher le documentPneumococcal vaccine: recommendations for use
Afficher le documentValaciclovir: neuropsychiatric reactions
Afficher le documentZanamivir: revisions to labelling
Afficher le documentCelecoxib: adverse reaction reports
Afficher le documentOlanzapine: serious reactions
Afficher le documentInfliximab approved for rheumatoid arthritis
Afficher le documentTenecteplase: the first "clot buster"
Afficher le documentBupropion: a new approach to smoking cessation
Afficher le documentDoxorubicin for ovarian cancer
Afficher le documentLinezolid: the first oxazolide antimicrobial approved
Afficher le documentGuidance for adverse reactions labelling
Afficher le documentLegislation adopted in Europe on orphan drugs
Afficher le documentMore drug safety measures planned in Japan
Afficher le document"Street drug alternatives" are not dietary supplements
Afficher le documentTamsulosin: syncope now reported
Afficher le documentDapsone hypersensitivity syndrome
Afficher le documentKava extract linked to hepatitis
Afficher le documentGene therapy and patient protection
Ouvrir ce répertoire et afficher son contenuEssential Drugs - WHO Model Prescribing Information
Ouvrir ce répertoire et afficher son contenuRecent Publications and Sources of Information
Afficher le documentProposed International Nonproprietary Names: List 83
Afficher le documentSelected WHO Publications of Related Interest
 

Valaciclovir: neuropsychiatric reactions

Australia - Valaciclovir is an antiviral prodrug of aciclovir used in the treatment of herpes infections.

The Adverse Drug Reactions Advisory Committee has received 69 reports of minor reactions including headache, nausea, rash, dizziness. However, 13 more severe neuropsychiatric reactions have been reported and include hallucination, confusion, delirium, ataxia, dysarthria, convulsions, psychosis and stupor. Of these, all but one occurred in patients with chronic renal failure or age-related renal impairment. Although this is consistent with the product information physicians should be made aware of the possibility of these risks.

Reference: Australian Adverse Drug Reactions Bulletin, 19: 2 (2000).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013